GMOs & Food Quality
Obesity
FDA & Big Pharma
Environment & Pollution

FDA & Perscription Drugs


Pfizer Ponies Up $2.3 Billion for Drug Crimes

Pfizer has agreed to pay $2.3 billion to settle criminal and civil liability due to its illegal off-label promotion of Bextra (a painkiller already pulled from the market), Geodon (like Zyprexa, an atypical antipsychotic that injures children), Zyvox (an antibiotic), and Lyrica (an epilepsy drug). Pfizer will plead guilty to one felony count violation of the Food, Drug and Cosmetic Act for misbranding Bextra with the intent to defraud.



Talk About Pulling The Plug On Grandma

The debate on health care reform is heating up. Americans are starting to pay attention to what is going on. Big Pharma, in a panic, has bought protection from the Obama administration. The Obama administration, fearing for its political life, has struck an 11th hour deal with the slimiest industry in the free world – change we can count on?



How the FDA is Becoming a Drug Company: Consumer Safety, Access to Natural Health Options Threatened

Under the false pretense of improved food and drug safety the FDA is re-inventing itself as a kingpin drug company. This charade has so far hoodwinked virtually all members of Congress. The Senate has already approved this FDA transformation.



Neurontin and Lyrica are a Death Sentence for New Brain Synapses

Neurontin and its newer more potent version, Lyrica, are widely used for off-label indications that are an outright flagrant danger to the public. These blockbuster drugs were approved for use even though the FDA had no idea what they actually did in the brain. A shocking new study shows that they block the formation of new brain synapses, drastically reducing the potential for rejuvenating brain plasticity – meaning that these drugs will cause brain decline faster than any substance known to mankind.



Avandia Linked to Heart Failure – FDA to Blame

The simple fact that Avandia remains on the market is a testament to ongoing abysmal corruption at the FDA. The latest study is published in the British Medical Journal and concludes, “Our findings suggest clinically important differences in the cardiovascular safety profiles of rosiglitazone [Avandia] and pioglitazone (Actos] in clinical practice. Given the accumulating evidence of harm with rosiglitazone treatment and the lack of a distinct clinical advantage for the drug over pioglitazone, it is reasonable to question whether ongoing use of rosiglitazone is justified.”



FDA Sides with Big Pharma on Bone Drugs

FDA management is doing everything in its power to keep the Big Pharma bubble from bursting. Actually, the Big Pharma bubble is more like a balloon that is gradually deflating. Massive layoffs, reduced ad spending, and huge liability from injury suits are occurring as the public is beginning to see that the Big Pharma racket is needlessly killing and injuring hundreds of thousands of Americans every year.